Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

mipasetamab uzoptirine

An antibody-drug conjugate (ADC), consisting of mipasetamab, a humanized immunoglobulin (Ig) G1 monoclonal antibody directed against AXL receptor tyrosine kinase (AXL; UFO) that is site-specifically conjugated to uzoptitine (PL1601), which contains a valine-alanine cleavable linker and SG3199, a cytotoxic pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of mipasetamab uzoptirine, mipasetamab binds to AXL, which is expressed on the surfaces of a variety of cancer cell types. Upon endocytosis and enzymatic cleavage, SG3199 is released and forms highly cytotoxic DNA interstrand cross-links, thereby blocking cell division and killing AXL-expressing cancer cells. AXL, a member of the TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases, is overexpressed by many tumor cell types, and plays a key role in tumor cell proliferation, survival, invasion and metastasis; its expression is associated with drug resistance and poor prognosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC ADCT-601
anti-AXL/PBD ADC ADCT-601
anti-AXL/PBD antibody-drug conjugate ADCT-601
Code name:ADCT 601
ADCT-601
ADCT601
BGB 601
BGB-601
BGB601
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search